ZURA — Zura Bio Ltd
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1855644 ·
Last close
$1.03
Market Cap
$99.70M
52W High
$7.44
52W Low
$0.93
ADV30
7,087,210
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -28,773,000 | -25,825,000 | 194,629,000 | 187,652,000 | 16,969,000 |
| Jun 2026 | 0 | — | -29,321,000 | -26,304,000 | 213,403,000 | 205,134,000 | 16,318,000 |
| Mar 2026 | 0 | — | -25,499,000 | -24,223,000 | 228,641,000 | 225,594,000 | 11,745,000 |
| Dec 2025 | 0 | — | -18,411,000 | -17,175,000 | 113,948,000 | 109,407,000 | 12,410,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,600,000
Investing CF
$-90,000
Financing CF
$130,325,000
CapEx
$-90,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.84
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-300,899,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-102,004,000
Pretax Income TTM
$-94,829,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -75,246,000 | -68,650,000 | 113,948,000 | 12,410,000 | 101,538,000 | -64,815,000 |
| Dec 2024 | 0 | -55,189,000 | -52,403,000 | 179,533,000 | 19,514,000 | 146,815,000 | -28,076,000 |
| Dec 2023 | 0 | -62,638,000 | -60,360,000 | 100,843,000 | 21,292,000 | 59,330,000 | -15,054,000 |
| Dec 2022 | 0 | -27,162,000 | -25,738,000 | 5,262,000 | 27,318,000 | -32,056,000 | -1,202,000 |
TTM Snapshot
Revenues TTM
$-6,041,000
NetIncome TTM
$-85,742,000
OpCashFlow TTM
—
Assets (Latest)
$213,403,000
Forward EPS
$-0.68
Max Pain — expiry 2026-12-18
max pain strike: $1.00 · spot: $0.96 · call oi: 656 · put oi: 1,684
Expected Move to 2026-12-18:
±$0.24
(24.87%) —
implied range
$0.72 –
$1.20
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARMP | Armata Pharmaceuticals, Inc. | $98.93M | $2.66 | — |
| VYGR | Voyager Therapeutics, Inc. | $94.59M | $1.52 | — |
| CMPX | Compass Therapeutics, Inc. | $109.26M | $0.61 | — |
| MOLN | MOLECULAR PARTNERS AG | $109.55M | $2.86 | — |
| LENZ | LENZ Therapeutics, Inc. | $109.97M | $3.50 | — |
News headlines (Yahoo Finance, 1h cache)
Zura Bio discontinues tibulizumab in HS after Phase II trial failure
2026-11-10 10:59 · Yahoo
Zura Bio Discontinues Hidradenitis Suppurativa Development After Phase 2 Tibulizumab Trial Misses Endpoints
2026-11-09 15:59 · Yahoo
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
2026-11-09 12:00 · Yahoo
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-27 22:00 · Yahoo
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
2026-10-27 11:30 · Yahoo
This biotech stock is a top pick at Guggenheim
2026-10-07 08:00 · Yahoo
Zura Bio to Participate in the Cantor Global Healthcare Conference
2026-08-31 20:30 · Yahoo
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
2026-05-13 11:30 · Yahoo
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 11:30 · Yahoo
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-14 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.